Edward Stopke
Edward Stopke is a financial analyst with BioMedTracker and has been with Sagient Research for three years. He is responsible for day-to-day analysis with the BioMedTracker analyst team, and works with the scientific analysts to determine the financial and market impact of early-stage drugs. In his time with Sagient, Stopke has gained an understanding of the pharmaceutical and biotech development process, in order to develop revenue models for various indications. Stopke received a bachelor's degree in economics from San Diego State University.
Recent Quotes
"One smaller company I like is CPXX."
—
The Life Sciences Report Interview with Ed Stopke
(1/22/15)
more >
"ATHX completed enrollment in its Phase 2 stroke study before the new year, so the first 90-day results will emerge in Q1/15E."
—
The Life Sciences Report Interview with Edward Stopke
(1/22/15)
more >
"The research synergy with Gilead and Merck could prove fruitful for RNN in terms of acquisition potential."
—
The Life Sciences Report Interview with Edward Stopke
(1/22/15)
more >
"If all goes well, CUR's NSI-189 product will move into Phase 2 development in Q2/15, so that is a good advancement opportunity."
—
The Life Sciences Report Interview with Edward Stopke
(1/22/15)
more >
